We are live on ! Find out more
NVCR icon

NovoCure

271 hedge funds and large institutions have $4.75B invested in NovoCure in 2020 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 103 increasing their positions, 82 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 39

26% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 82

3% more funds holding

Funds holding: 262271 (+9)

0.63% more ownership

Funds ownership: 70.14%70.77% (+0.63%)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

19% less capital invested

Capital invested by funds: $5.83B → $4.75B (-$1.09B)

21% less call options, than puts

Call options by funds: $80.5M | Put options by funds: $102M

Holders
271
Holders Change
+9
Holders Change %
+3.44%
% of All Funds
5.97%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.13%
New
50
Increased
103
Reduced
82
Closed
39
Calls
$80.5M
Puts
$102M
Net Calls
-$21.7M
Net Calls Change
-$32.2M

NVCR Hedge Fund Activity: Q1 2020 in Review

271 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q1 2020, worth a combined $4.75B — down 19% from $5.83B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new NVCR positions and 39 closed out — a net gain of 11 holders — while 103 added to existing stakes and 82 trimmed.

The largest buyer was Capital International Investors, adding an estimated $92.9M. The largest seller was Fidelity Investments, cutting an estimated $26.9M.

  • 271 institutional investors held NovoCure (NVCR) as of Q1 2020, up from 262 in Q4 2019.
  • Funds reported $4.75B of NovoCure stock for Q1 2020, down 19% quarter-over-quarter.
  • 50 funds opened new NovoCure positions in Q1 2020 and 39 closed out, a net change of +11 holders.
  • The largest NovoCure buyer in Q1 2020 was Capital International Investors, an estimated $92.9M added.
  • The largest NovoCure seller in Q1 2020 was Fidelity Investments, an estimated $26.9M sold.

Based on aggregated 13F filings for Q1 2020.